Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Investor profile

OrbiMed

Private equity / VC · Founded 1989 · Active in 2026

A public taster of the full Dealroom platform — request a demo to explore live deal flow, full investor history, and team intel.

102 Power Law outcomes Power Law Ranking #98 · Global · 102 Power Law outcomes · Active 2026
Unicorns ↑ 42% 5y
74
Decacorns ↑ 75% 5y
7
Thoroughbreds ↑ 48% 5y
44
Featured in #98Power Law Investor Ranking · Global · 2026Top 0.5%

OrbiMed is a private equity / vc based in USA, founded in 1989. The page below shows 102 Power Law outcomes from OrbiMed's portfolio — 74 unicorns ($1B+ valuation) and 8 additional thoroughbreds (companies that crossed $100M+ in revenue without yet reaching $1B+ valuation).

Outcomes are concentrated in Biotech & Life Sciences · Health Tech & Medtech; top portfolio geographies are USA · China · Canada. OrbiMed ranks #98 in Global in the 2026 Dealroom Power Law Investor Ranking by cross-stage outcomes.

Portfolio analysis

The 102 OrbiMed Power Law outcomes ($100M+ revenue or $1B+ valuation).

Snapshot of where the outcomes are concentrated by country, sector, and stage entered.

By countryCount
  1. USA79
  2. China7
  3. Canada5
  4. UK4
  5. Denmark2
  6. Belgium1
  7. India1
  8. Netherlands1
  9. Switzerland1
  10. France1
By sectorCount
  1. Biotech & Life Sciences99
  2. Health Tech & Medtech3
By stage enteredCount
  1. Series B+61
  2. Series A22
  3. Seed1
01 · Portfolio market map

OrbiMed's 102 Power Law outcomes.

Stage entered
Outcome tier
Region
Group by
102 of 102 Power Law outcomes
02 · Founder talent

Where OrbiMed's founders come from — and where they study.

74 founders across the 102 Power Law outcomes — split by country of origin, university attended, and the company they worked at before founding. Aarhus University and Aiolos Bio are the deepest single pipelines.

LocationCount
United States30
United Kingdom12
India5
Belgium4
France4
Denmark3
China2
Singapore2
Argentina1
Netherlands1
+4 more →
UniversityCount
Aarhus University3
Stanford University3
Institute of Management Technology,Ghaziabad2
Aston University2
University of Bristol2
North Carolina State University2
UCLA2
MIT Sloan School of Management2
Massachusetts Institute of Technology2
Washington University in St. Louis2
+32 more →
Origin companyCount
Aiolos Bio3
Five Prime Therapeutics2
Gyroscope Therapeutics2
Immunocore1
MakeMyTrip1
Turnstone Biologics1
Forward Pharma1
Nektar Therapeutics1
Acerta Pharma1
Natera1
+14 more →
Origin = country a founder is born in or grew up in (founders may have multiple origins; counts include all entries). University = highest-listed degree. Origin company = a previous employer where the founder was tagged before starting their current company.
03 · Key people

Key people at OrbiMed.

Senior investment team at OrbiMed has not been published on this profile yet.
Suggest the partner roster →
04 · Compare with peers

How does OrbiMed stack up?

OrbiMed in orange, your selection in blue and other colours. Pick from the global roster of 35 peer investors — scope by startup location or hit "Find similar shapes" to auto-pick the three closest. The funnel matrix mirrors the spider chart on the ranking page; the line chart shows each firm's share of unicorns minted in the selected startup location — peaks reveal vintage years.

Compare against

Share of new unicorns per year

% of global unicorns minted that year, year by year · hover the chart to see which unicorns

Stage focus

Companies by entry stage and outcome tier

Sector focus

Companies per investor across the 10 highest-volume sectors
Source: Dealroom Power Law dataset. Investors shown are the 2026 Power Law top 35 by combined entry-to-outcome score, drawn from the overview and locations_data sheets. Funnel-matrix axes rescale per-axis using the maximum among the currently selected investors, so the polygons always fill the chart for shape comparison.

Sentiment on X

What X is saying about OrbiMed

An AI-synthesized read of the highest-engagement posts about OrbiMed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

In the news

Latest news about OrbiMed

Recent press, funding announcements, and portfolio moves mentioning OrbiMed — pulled live from Dealroom's news feed.

See all news

Want the full picture on OrbiMed?

The Dealroom platform tracks every round, every co-investor, and every portfolio company in real time — across 25,000+ investors and 3M+ companies globally.

View OrbiMed in app → Book a demo